Evolent Health (EVH) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Evolent Health (NYSE: EVH) in the last few weeks:

• 2/12/2025 – Evolent Health had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
• 1/28/2025 – Evolent Health had its price target lowered by analysts at JPMorgan Chase & Co. from $15.00 to $13.00. They now have an “overweight” rating on the stock.
• 1/24/2025 – Evolent Health had its price target lowered by analysts at Oppenheimer Holdings Inc. from $28.00 to $18.00. They now have an “outperform” rating on the stock.
• 1/23/2025 – Evolent Health had its price target lowered by analysts at Canaccord Genuity Group Inc. from $23.00 to $16.00. They now have a “buy” rating on the stock.
• 1/22/2025 – Evolent Health had its price target lowered by analysts at Truist Financial Co. from $20.00 to $15.00. They now have a “buy” rating on the stock.
• 1/21/2025 – Evolent Health had its price target lowered by analysts at Stephens from $16.00 to $12.00. They now have an “equal weight” rating on the stock.
• 1/16/2025 – Evolent Health had its price target lowered by analysts at UBS Group AG from $27.00 to $14.00. They now have a “buy” rating on the stock.
• 1/14/2025 – Evolent Health had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an “outperform” rating on the stock.
• 1/13/2025 – Evolent Health had its price target lowered by analysts at Truist Financial Co. from $24.00 to $20.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Evolent Health had its price target lowered by analysts at JMP Securities from $27.00 to $18.00. They now have a “market outperform” rating on the stock.
• 1/10/2025 – Evolent Health had its price target lowered by analysts at Citigroup Inc. from $21.00 to $18.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Evolent Health is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $15.00 price target on the stock.

Evolent Health Trading Up 3.7 %

Shares of NYSE:EVH traded up $0.36 during trading on Thursday, hitting $9.96. The company had a trading volume of 1,328,391 shares, compared to its average volume of 2,101,669. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -10.94 and a beta of 1.45. Evolent Health, Inc. has a one year low of $9.45 and a one year high of $35.00. The company has a fifty day simple moving average of $10.91 and a two-hundred day simple moving average of $19.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Institutional Trading of Evolent Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Evolent Health by 12.8% in the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after buying an additional 1,426,747 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Evolent Health by 1,948.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock valued at $42,289,000 after purchasing an additional 1,422,385 shares in the last quarter. Boston Partners increased its stake in shares of Evolent Health by 92.0% in the 4th quarter. Boston Partners now owns 2,444,006 shares of the technology company’s stock valued at $27,097,000 after purchasing an additional 1,171,304 shares in the last quarter. Norges Bank purchased a new position in shares of Evolent Health in the 4th quarter valued at about $12,519,000. Finally, Bellevue Group AG increased its stake in shares of Evolent Health by 59.9% in the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock valued at $75,509,000 after purchasing an additional 1,000,215 shares in the last quarter.

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.